The fund giant’s portfolio has returned more than $488 billion in the past three years alone to boost its total asset value to $1.38 trillion.

The market has more to fall, so investing now makes no sense, according to the firm’s technical analyst, Rich Ross.

Terminating the $1.3 billion plan is significant because the pharmaceutical industry is one of the few strongholds for DB plans, according to a Willis Towers Watson report.

The shenanigans of its scheming characters may seem absurd, but they have real-world applications.